SK3612000A3 - Sustained release tablet formulation to treat parkinson disease - Google Patents
Sustained release tablet formulation to treat parkinson disease Download PDFInfo
- Publication number
- SK3612000A3 SK3612000A3 SK361-2000A SK3612000A SK3612000A3 SK 3612000 A3 SK3612000 A3 SK 3612000A3 SK 3612000 A SK3612000 A SK 3612000A SK 3612000 A3 SK3612000 A3 SK 3612000A3
- Authority
- SK
- Slovakia
- Prior art keywords
- hydroxypropylmethylcellulose
- pharmaceutical composition
- cps
- methylamino
- composition according
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title claims abstract description 13
- 239000007939 sustained release tablet Substances 0.000 title claims abstract description 8
- 239000000203 mixture Substances 0.000 title claims description 47
- 238000009472 formulation Methods 0.000 title description 8
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims abstract description 18
- 239000003826 tablet Substances 0.000 claims description 35
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 25
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims description 22
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 19
- 229920002472 Starch Polymers 0.000 claims description 18
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 17
- 235000019698 starch Nutrition 0.000 claims description 17
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 16
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 16
- 239000008107 starch Substances 0.000 claims description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 229940031702 hydroxypropyl methylcellulose 2208 Drugs 0.000 claims description 11
- -1 hydroxypropyl Chemical group 0.000 claims description 10
- 229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 229920002261 Corn starch Polymers 0.000 claims description 7
- 229920000881 Modified starch Polymers 0.000 claims description 7
- 239000008119 colloidal silica Substances 0.000 claims description 6
- 239000008120 corn starch Substances 0.000 claims description 6
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 3
- IRFHMTUHTBSEBK-QGZVFWFLSA-N tert-butyl n-[(2s)-2-(2,5-difluorophenyl)-3-quinolin-3-ylpropyl]carbamate Chemical compound C1([C@H](CC=2C=C3C=CC=CC3=NC=2)CNC(=O)OC(C)(C)C)=CC(F)=CC=C1F IRFHMTUHTBSEBK-QGZVFWFLSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- 229940032147 starch Drugs 0.000 description 13
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000007916 tablet composition Substances 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 239000002480 mineral oil Substances 0.000 description 5
- 235000010446 mineral oil Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000538 analytical sample Substances 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- QGICDLYPUUZBIV-SECBINFHSA-N (2r)-2-(methoxycarbonylamino)-3-phenylpropanoic acid Chemical compound COC(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 QGICDLYPUUZBIV-SECBINFHSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- LDECUSDQMXVUMP-UHFFFAOYSA-N benzyl 3-[6-[[2-(butylamino)-1-[3-methoxycarbonyl-4-(2-methoxy-2-oxoethoxy)phenyl]-2-oxoethyl]-hexylamino]-6-oxohexyl]-4-methyl-2-oxo-6-(4-phenylphenyl)-1,6-dihydropyrimidine-5-carboxylate Chemical compound O=C1NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)C(C(=O)OCC=2C=CC=CC=2)=C(C)N1CCCCCC(=O)N(CCCCCC)C(C(=O)NCCCC)C1=CC=C(OCC(=O)OC)C(C(=O)OC)=C1 LDECUSDQMXVUMP-UHFFFAOYSA-N 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- UPCAUQHSJMAOFY-SNVBAGLBSA-N methyl n-[(2r)-1-(methoxyamino)-1-oxo-3-phenylpropan-2-yl]carbamate Chemical compound CONC(=O)[C@H](NC(=O)OC)CC1=CC=CC=C1 UPCAUQHSJMAOFY-SNVBAGLBSA-N 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000010409 thin film Substances 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- PEZNEXFPRSOYPL-UHFFFAOYSA-N (bis(trifluoroacetoxy)iodo)benzene Chemical compound FC(F)(F)C(=O)OI(OC(=O)C(F)(F)F)C1=CC=CC=C1 PEZNEXFPRSOYPL-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- 229920000856 Amylose Polymers 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- VSTVPNVVKXAOLZ-QGZVFWFLSA-N benzyl n-[(3r)-1-(methoxycarbamoyl)-3,4-dihydro-2h-quinolin-3-yl]-n-methylcarbamate Chemical compound CN([C@H]1CN(C2=CC=CC=C2C1)C(=O)NOC)C(=O)OCC1=CC=CC=C1 VSTVPNVVKXAOLZ-QGZVFWFLSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 2
- OYOBVWWEHGQJHB-SECBINFHSA-N methyl n-[(3r)-1-methoxy-2-oxo-3,4-dihydroquinolin-3-yl]carbamate Chemical compound C1=CC=C2N(OC)C(=O)[C@H](NC(=O)OC)CC2=C1 OYOBVWWEHGQJHB-SECBINFHSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VOJRMYBBPKNLLI-ORHWHDKWSA-N sumanirole maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@H](C1)NC)C2=CC=CC3=C2N1C(=O)N3 VOJRMYBBPKNLLI-ORHWHDKWSA-N 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- IQDMUSPYIULEGD-SECBINFHSA-N (3r)-n-methyl-1,2,3,4-tetrahydroquinolin-3-amine Chemical compound C1=CC=C2C[C@@H](NC)CNC2=C1 IQDMUSPYIULEGD-SECBINFHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
- 229930182832 D-phenylalanine Natural products 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 244000007853 Sarothamnus scoparius Species 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- MJSHDCCLFGOEIK-UHFFFAOYSA-N benzyl (2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)OCC1=CC=CC=C1 MJSHDCCLFGOEIK-UHFFFAOYSA-N 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- CNRFRMQVMVEMAF-MRXNPFEDSA-N benzyl n-methyl-n-[(3r)-1,2,3,4-tetrahydroquinolin-3-yl]carbamate Chemical compound CN([C@@H]1CC2=CC=CC=C2NC1)C(=O)OCC1=CC=CC=C1 CNRFRMQVMVEMAF-MRXNPFEDSA-N 0.000 description 1
- CCDWGDHTPAJHOA-UHFFFAOYSA-N benzylsilicon Chemical compound [Si]CC1=CC=CC=C1 CCDWGDHTPAJHOA-UHFFFAOYSA-N 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 150000002689 maleic acids Chemical class 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 229920001921 poly-methyl-phenyl-siloxane Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6082797P | 1997-09-30 | 1997-09-30 | |
| PCT/US1998/017992 WO1999016442A2 (fr) | 1997-09-30 | 1998-09-03 | Formulation de comprimes a degagement prolonge pour le traitement de la maladie de parkinson |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK3612000A3 true SK3612000A3 (en) | 2000-09-12 |
Family
ID=22031996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK361-2000A SK3612000A3 (en) | 1997-09-30 | 1998-09-03 | Sustained release tablet formulation to treat parkinson disease |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US6197339B1 (fr) |
| EP (1) | EP1017391B1 (fr) |
| JP (1) | JP2001517701A (fr) |
| KR (1) | KR100516095B1 (fr) |
| CN (1) | CN1195518C (fr) |
| AT (1) | ATE297208T1 (fr) |
| AU (1) | AU742941B2 (fr) |
| BR (1) | BR9812687A (fr) |
| CA (1) | CA2301869A1 (fr) |
| DE (1) | DE69830503T2 (fr) |
| DK (1) | DK1017391T3 (fr) |
| ES (1) | ES2242296T3 (fr) |
| FI (1) | FI20000720A (fr) |
| HK (1) | HK1030163A1 (fr) |
| HU (1) | HUP0004586A2 (fr) |
| NO (1) | NO320303B1 (fr) |
| NZ (1) | NZ504221A (fr) |
| PL (1) | PL191125B1 (fr) |
| PT (1) | PT1017391E (fr) |
| RU (1) | RU2205007C2 (fr) |
| SI (1) | SI1017391T1 (fr) |
| SK (1) | SK3612000A3 (fr) |
| WO (1) | WO1999016442A2 (fr) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2358865A1 (fr) | 1999-02-05 | 2000-08-10 | Pharmacia & Upjohn Company | Procede de preparation de (5r)-(methylamino)-5,6-dihydro-4h-imidazo[4,5,1-ij]-quinoline-2(1h)-one |
| CA2371940C (fr) | 1999-03-31 | 2008-07-15 | Janssen Pharmaceutica N.V. | Amidon pregelatinise dans une formulation a liberation regulee |
| AR031152A1 (es) * | 2000-10-31 | 2003-09-10 | Upjohn Co | Tratamientos nuevos para el sindrome de piernas inquietas |
| FR2825705B1 (fr) * | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
| US20060281797A1 (en) * | 2001-12-11 | 2006-12-14 | University Of Virginia Patent Foundation | Neurorestoration with R(+) Pramipexole |
| US7157480B2 (en) * | 2001-12-11 | 2007-01-02 | University Of Virginia Patent Foundation | Use of pramipexole to treat amyotrophic lateral sclerosis |
| FR2835186B1 (fr) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| AU2003225837B2 (en) * | 2002-03-15 | 2008-11-06 | Forest Laboratories Holdings Limited | NE and 5-HT reuptake inhibitors for treating visceral pain syndromes |
| US20070196481A1 (en) * | 2002-07-25 | 2007-08-23 | Amidon Gregory E | Sustained-release tablet composition |
| US20050226926A1 (en) * | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
| US20050079217A1 (en) * | 2002-07-25 | 2005-04-14 | Ganorkar Loksidh D. | Sustained-release tablet composition comprising a dopamine receptor agonist |
| MY142204A (en) | 2002-07-25 | 2010-10-29 | Pharmacia Corp | Pramipexole once-daily dosage form |
| FR2844273B1 (fr) | 2002-09-05 | 2008-04-04 | Aventis Pharma Sa | Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens. |
| MXPA05003513A (es) * | 2002-10-04 | 2005-06-03 | Pharmacia Corp | Composiciones farmaceuticas para tratamiento de enfermedad de parkinson. |
| EP1545521A2 (fr) * | 2002-10-04 | 2005-06-29 | Pharmacia Corporation | Compositions et methodes permettant le traitement des dysfonctions sexuelles |
| PL376452A1 (en) * | 2002-10-25 | 2005-12-27 | Pharmacia & Upjohn Company Llc | Use of heterocyclic amine-type compounds as neuroprotective agents |
| US20060003004A1 (en) * | 2002-10-25 | 2006-01-05 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
| US20040132826A1 (en) * | 2002-10-25 | 2004-07-08 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
| JP2006515008A (ja) * | 2003-01-28 | 2006-05-18 | コレギウム ファーマシューティカル， インコーポレイテッド | 経口投与のためのミルナシプランの多粒子状組成物 |
| US20050020589A1 (en) * | 2003-06-18 | 2005-01-27 | Pfizer Inc. | Sustained-release tablet composition comprising a dopamine receptor agonist |
| PL1789021T3 (pl) * | 2004-08-13 | 2012-04-30 | Boehringer Ingelheim Int | Preparat tabletkowy o przedłużonym uwalnianiu zawierający pramipeksol lub jego farmaceutycznie dopuszczalną sól |
| CA2576386A1 (fr) * | 2004-08-13 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Preparation d'une pastille a autorisation de sortie elargie, contenant du pramipexole ou un sel de pramipexole pharmaceutiquement acceptable, procede de fabrication et d'utilisation de cette pastille |
| JP2009504748A (ja) * | 2005-08-15 | 2009-02-05 | ユニバーシティ オブ バージニア パテント ファウンデーション | Ｒ（＋）プラミペキソールを用いた神経回復 |
| US20090098202A1 (en) * | 2006-02-10 | 2009-04-16 | Boehringer Ingelheim International Gmbh | Extended Release Formulation |
| US20090041844A1 (en) * | 2006-02-10 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Modified Release Formulation |
| US8518926B2 (en) * | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
| ES2379117T3 (es) | 2006-05-16 | 2012-04-20 | Knopp Neurosciences, Inc. | Composiciones de R(+) y S(-) pramipexol y métodos de utilización de las mismas |
| US8524695B2 (en) * | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
| JP2010521496A (ja) | 2007-03-14 | 2010-06-24 | ノップ ニューロサイエンシーズ、インク． | キラル精製置換ベンゾチアゾールジアミンの合成 |
| US20110190356A1 (en) * | 2008-08-19 | 2011-08-04 | Knopp Neurosciences Inc. | Compositions and Methods of Using (R)- Pramipexole |
| MX2014002996A (es) | 2011-09-23 | 2014-05-28 | Roche Glycart Ag | Anticuerpos anti - egfr/anti - igf-1r bisespecificos. |
| WO2013096816A1 (fr) | 2011-12-22 | 2013-06-27 | Biogen Idec Ma Inc. | Synthèse améliorée de composés substitués par amine de 4,5,6,7-tétrahydrobenzothiazole |
| US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
| US9463186B2 (en) | 2013-04-15 | 2016-10-11 | Northwestern University | Treatment for dopaminergic disorders |
| LT3019167T (lt) | 2013-07-12 | 2021-03-25 | Knopp Biosciences Llc | Eozinofilų ir (arba) bazofilų padidintų kiekių gydymas |
| US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
| AU2014306597B2 (en) | 2013-08-13 | 2018-05-17 | Knopp Biosciences Llc | Compositions and methods for treating chronic urticaria |
| EP3038467B1 (fr) | 2013-08-13 | 2020-07-29 | Knopp Biosciences LLC | Compositions et méthodes de traitement de troubles des cellules plasmatiques et de troubles prolymphocytaires à cellules b |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| JP2955358B2 (ja) * | 1989-06-09 | 1999-10-04 | ファルマシア・アンド・アップジョン・カンパニー | 中枢神経系活性を有する複素環系アミン |
| US5273975A (en) | 1989-06-09 | 1993-12-28 | The Upjohn Company | Heterocyclic amines having central nervous system activity |
| US5000962A (en) | 1989-08-25 | 1991-03-19 | Schering Corporation | Long acting diltiazem formulation |
| GB9605857D0 (en) | 1996-03-20 | 1996-05-22 | Tester Richard F | Polysaccharides as chemical release systems |
| CA2173818A1 (fr) | 1996-04-10 | 1997-10-11 | Francois Chouinard | Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose |
-
1998
- 1998-03-09 US US09/146,090 patent/US6197339B1/en not_active Expired - Fee Related
- 1998-09-03 PT PT98945805T patent/PT1017391E/pt unknown
- 1998-09-03 HU HU0004586A patent/HUP0004586A2/hu unknown
- 1998-09-03 AU AU92964/98A patent/AU742941B2/en not_active Ceased
- 1998-09-03 ES ES98945805T patent/ES2242296T3/es not_active Expired - Lifetime
- 1998-09-03 WO PCT/US1998/017992 patent/WO1999016442A2/fr active IP Right Grant
- 1998-09-03 JP JP2000513578A patent/JP2001517701A/ja not_active Withdrawn
- 1998-09-03 DK DK98945805T patent/DK1017391T3/da active
- 1998-09-03 RU RU2000111506/14A patent/RU2205007C2/ru not_active IP Right Cessation
- 1998-09-03 SK SK361-2000A patent/SK3612000A3/sk unknown
- 1998-09-03 EP EP98945805A patent/EP1017391B1/fr not_active Expired - Lifetime
- 1998-09-03 PL PL339946A patent/PL191125B1/pl not_active IP Right Cessation
- 1998-09-03 AT AT98945805T patent/ATE297208T1/de not_active IP Right Cessation
- 1998-09-03 KR KR10-2000-7003349A patent/KR100516095B1/ko not_active IP Right Cessation
- 1998-09-03 NZ NZ504221A patent/NZ504221A/en unknown
- 1998-09-03 DE DE69830503T patent/DE69830503T2/de not_active Expired - Fee Related
- 1998-09-03 CA CA002301869A patent/CA2301869A1/fr not_active Abandoned
- 1998-09-03 CN CNB988087170A patent/CN1195518C/zh not_active Expired - Fee Related
- 1998-09-03 SI SI9830770T patent/SI1017391T1/sl unknown
- 1998-09-03 BR BR9812687-3A patent/BR9812687A/pt not_active Application Discontinuation
-
2000
- 2000-03-29 FI FI20000720A patent/FI20000720A/fi unknown
- 2000-03-29 NO NO20001624A patent/NO320303B1/no unknown
-
2001
- 2001-01-11 US US09/759,286 patent/US20010053386A1/en not_active Abandoned
- 2001-02-21 HK HK01101251A patent/HK1030163A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US20010053386A1 (en) | 2001-12-20 |
| NZ504221A (en) | 2004-11-26 |
| CA2301869A1 (fr) | 1999-04-08 |
| DE69830503D1 (de) | 2005-07-14 |
| HUP0004586A2 (hu) | 2001-06-28 |
| PT1017391E (pt) | 2005-09-30 |
| JP2001517701A (ja) | 2001-10-09 |
| FI20000720A (fi) | 2000-03-29 |
| KR20010030776A (ko) | 2001-04-16 |
| DE69830503T2 (de) | 2006-03-16 |
| PL339946A1 (en) | 2001-01-15 |
| ES2242296T3 (es) | 2005-11-01 |
| DK1017391T3 (da) | 2005-08-22 |
| AU9296498A (en) | 1999-04-23 |
| WO1999016442A2 (fr) | 1999-04-08 |
| CN1195518C (zh) | 2005-04-06 |
| NO20001624D0 (no) | 2000-03-29 |
| BR9812687A (pt) | 2000-08-22 |
| CN1268890A (zh) | 2000-10-04 |
| HK1030163A1 (en) | 2001-04-27 |
| NO20001624L (no) | 2000-03-29 |
| WO1999016442A3 (fr) | 1999-06-17 |
| US6197339B1 (en) | 2001-03-06 |
| SI1017391T1 (sl) | 2005-12-31 |
| NO320303B1 (no) | 2005-11-21 |
| PL191125B1 (pl) | 2006-03-31 |
| RU2205007C2 (ru) | 2003-05-27 |
| EP1017391A2 (fr) | 2000-07-12 |
| ATE297208T1 (de) | 2005-06-15 |
| AU742941B2 (en) | 2002-01-17 |
| KR100516095B1 (ko) | 2005-09-23 |
| EP1017391B1 (fr) | 2005-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK3612000A3 (en) | Sustained release tablet formulation to treat parkinson disease | |
| ES2307219T3 (es) | Nebivolol y sus sales farmaceuticamente aceptables, procedimiento de preparacion y composiciones farmaceuticas de nebivolol. | |
| SK3898A3 (en) | Cyclic gmp-specific phosphodiesterase inhibitors | |
| FI75559C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 3-aminopropoxiarylderivat. | |
| CZ150596A3 (en) | Tetrahydrocarbazole derivatives, process of their preparation and pharmaceutical compositions containing thereof | |
| NZ242191A (en) | Crystalline tiagabine hydrochloride monohydrate, preparation and pharmaceutical compositions thereof | |
| WO2003082806A1 (fr) | Base de venlafaxine | |
| GB2619907A (en) | Novel crystalline salt forms of mesembrine | |
| WO1999047494A1 (fr) | Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament | |
| AU2004203910B2 (en) | Use of 2-amino-2H-quinazoline derivatives for producing therapeutic agents | |
| WO1995004056A1 (fr) | Amines heterocycliques presentant une activite sur le systeme nerveux central | |
| NL8800412A (nl) | Piperazinecarbonzuurderivaat, bereiding ervan en farmaceutische preparaten die het bevatten. | |
| EP1496053A1 (fr) | Agoniste du recepteur kappa-opio de comprenant un derive de 2-phenylbenzothiazoline | |
| JPH04178356A (ja) | 光学活性なベンジルアルコール誘導体及びその用途 | |
| JPS6230762A (ja) | 新規５−オキソ−１−イミダゾリジンアセトアミド誘導体 | |
| PL208284B1 (pl) | Pochodne benzo[g]chinoliny, kompozycje je zawierające oraz zastosowanie takich pochodnych | |
| CZ20001102A3 (cs) | Tabletová formulace pro trvalé uvolňování látky k léčbě Parkinsouovy nemoci | |
| PL215012B1 (pl) | Nowe pochodne benzo[g]chinoliny, kompozycje farmaceutyczne je zawierajace oraz zastosowania farmaceutyczne tych zwiazków | |
| CN115252583B (zh) | 复方盐酸替利定缓释制剂及其制备方法 | |
| MXPA00002986A (en) | Sustained release tablet formulation to treat parkinson disease | |
| US4198414A (en) | Compounds and methods for treating diabetic complications | |
| WO2023086432A1 (fr) | Promédicaments d'analogues de neurostéroïdes et leurs utilisations | |
| TW202434240A (zh) | 苯並氮雜芳環衍生物的藥物組合物及其在醫藥上的應用 | |
| AU607621B2 (en) | Novel esters of estramustine | |
| NO152750B (no) | Fremgangsmaate for fremstilling av nitrogen brohode-kondenserte pyrimidinforbindelser |